167 related articles for article (PubMed ID: 33313471)
1. Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results.
John MJ; Chakrabarti P; Apte S; Bhattacharyya M; S C; Hansen T; Kolla R; Ross C; Seth T; Siddharthan N; Abraham A
Res Pract Thromb Haemost; 2020 Nov; 4(8):1324-1330. PubMed ID: 33313471
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.
Wu R; Sun J; Xu W; Hu Q; Li W; Xiao J; Yang F; Zeng X; Zeng Y; Zhou J; Matytsina I; Zhang S; Pluta M; Yang R
Ther Clin Risk Manag; 2020; 16():567-578. PubMed ID: 32606716
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
4. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
5. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
[TBL] [Abstract][Full Text] [Related]
6. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
8. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
Takedani H; Hirose J
Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
Boban A; Hermans C
Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
[No Abstract] [Full Text] [Related]
10. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
Benson G; Morton T; Thomas H; Lee XY
Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
[TBL] [Abstract][Full Text] [Related]
12. Turoctocog alfa for the treatment of hemophilia A.
Haddley K
Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
[TBL] [Abstract][Full Text] [Related]
13. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.
Lentz SR; Kavakli K; Klamroth R; Misgav M; Nagao A; Tosetto A; Jørgensen PJ; Zak M; Nemes L
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12674. PubMed ID: 35308099
[TBL] [Abstract][Full Text] [Related]
14. Turoctocog alfa for the treatment of hemophilia a.
Vakil NH; Fujinami N; Martin-Stone S
Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
[TBL] [Abstract][Full Text] [Related]
16. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.
Nagao A; Deguchi A; Nogami K
Hematology; 2024 Dec; 29(1):2316540. PubMed ID: 38376107
[TBL] [Abstract][Full Text] [Related]
17. Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India.
Choraria N; Rangarajan S; John MJ; Apte S; Gupta P; Pai S; Chand R; Parvatini S; Ramakanth GSH; Rupon J; Chhabra A; Muley HB; Simoneau D
Indian J Hematol Blood Transfus; 2022 Nov; 39(4):1-6. PubMed ID: 36467512
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
Drillaud N; Cussac V; Bertho PO; Horvais V; Beurrier P; Ternisien C; Rose J; Fouassier M; Babuty A; Trossaërt M
Transfusion; 2023 Dec; 63(12):2321-2327. PubMed ID: 37850587
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
[TBL] [Abstract][Full Text] [Related]
20. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]